Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound topical combination drug for treatment of acne and preparation method thereof

A drug and compound technology, applied in the field of compound external combination drugs and their preparation, can solve the problems of single, at most 1-2, many adverse reactions, single effect, etc., to achieve good patient compliance and reduce skin dryness. , Easy to spread effect

Active Publication Date: 2010-07-14
AIR FORCE MEDICAL CENT PLA
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of the existing acne treatment drugs are unilateral, and the effect is relatively single. For example, the drugs mainly for inflammatory acne are mostly antibiotics, including metronidazole, erythromycin, clindamycin, and chloramphenicol, which mainly play an antibacterial role. , with anti-inflammatory effects; and the main drugs for non-inflammatory acne are retinoic acid, benzoyl peroxide, salicylic acid, lactic acid, etc.
The main problem of unilateral therapy is that on the one hand, it has a single effect, and it can only target 1-2 disease links at most (such as antibacterial plus anti-inflammatory, or antibacterial plus anti-angular tie); on the other hand, some oral preparations have many adverse reactions, even some External preparations, due to the side effects of the drug itself, there will be adverse reactions such as dryness, desquamation, erythema, redness, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] The effective active ingredients of this embodiment adopt all-trans retinoic acid 0.025% (weight percentage, the same below), clindamycin phosphate 1% (calculated as clindamycin) and metronidazole 2%, and the matrix carrier adopts Carbomer, humectant urea and glycerin, transdermal absorbent dimethyl sulfoxide, propylene glycol, azone, etc., antioxidants, metal ion chelating agents, preservatives, solubilizers, ethanol, etc.

Embodiment 2

[0024] The effective active ingredient of this embodiment adopts tazarotene 0.03%, clindamycin hydrochloride 1% (calculated as clindamycin) and metronidazole 1.5%, matrix carrier adopts carbomer, humectant urea, transdermal Absorbent dimethyl sulfoxide, propylene glycol, azone, etc., antioxidants, metal ion chelating agents, preservatives, solubilizers, ethanol, etc.

Embodiment 3

[0026]The effective active ingredient of this embodiment adopts all-trans retinoic acid 0.025%, clindamycin hydrochloride 1% (calculated as clindamycin) and tinidazole 2%, matrix carrier adopts carbomer, humectant glycerin and Urea, transdermal absorbent dimethyl sulfoxide, propylene glycol, azone, etc., antioxidants, metal ion chelating agents, preservatives, solubilizers, ethanol, etc.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound topical combination drug for treatment of acne and a preparation method thereof. The compound topical combination drug is characterized in that a matrix carrier of the compound topical drug contains the following active components (by weight percent): 0.01-2.5 percent of retinoid acid, 0.2-10 percent of two antibacterial drugs, and 0.01-1 percent of estrogen or1-10 percent of spironolactone. The applied dosage forms are gel, ointment, liniment, film, film coating agent, sprays and the like, and the gels, the ointment, the liniment and the film coating agent are preferred. The preparation method comprises the following steps: dissolving the main drug with a suitable solvent system, adding into the matrix, adding corresponding and necessary auxiliary materials and mixing to obtain the combination drug. The invention has the advantages that: the main drug contains the retinoid acid, two antibacterial drugs, and estrogen or spironolactone, the prescription combination is scientific so as to simultaneously play three or more therapeutic effects (adjusting the sebaceous gland function, resisting keratinization abnormalities, inflammation and microbe,performing like estrogen and the like), and thereby curing the acne more comprehensively and intensively. Humectants such as carbamide is added in the drug so as to reduce side effects such as skin dryness, desquamation, erythema and the like, and no adverse reactions such as stimulus and allergy are caused during animal experiments. The preferred drug dosage forms have strong coupling effect with the skin, are easy to be applied and spread, can not pollute the clothes, and have good patient compliance and accurate clinical therapeutic effect.

Description

technical field [0001] The invention relates to a compound medicine for external use for treating acne and a preparation method thereof. Background technique [0002] Acne is a chronic disease of the pilosebaceous glands. It can be divided into two types: inflammatory and non-inflammatory acne. The incidence of acne is relatively high. According to relevant data reports, nearly 80% of people aged 12 to 25 suffer from acne, and the age of the disease covers 11 to 30 years old. Both men and women suffer from it. [0003] The following four types of acne pathogenesis are known: 1. The effect of free microorganisms in hair follicles and sebaceous units, mainly Propionibacterium acnes; / or 5a-reductase activity is enhanced, which increases the highly active 2H-testosterone; the latter mainly refers to androgen-dependent sebaceous gland hyperplasia and increased sebum secretion; 3. Abnormal keratinization of pilosebaceous gland ducts, which eventually leads to the formation of ac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7056A61K31/203A61K31/4164A61K31/585A61K31/565A61K47/16A61P17/10A61P31/04A61P29/00
Inventor 吴燕张福成刘丽平
Owner AIR FORCE MEDICAL CENT PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products